Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$8.7 million.

  • Cartesian Therapeutics' Cash from Investing Activities rose 79.16% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 181.12%. This contributed to the annual value of -$8.7 million for FY2024, which is 125.26% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Cash from Investing Activities stood at -$8.7 million for FY2024, which was down 125.26% from $34.6 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Cash from Investing Activities registered a high of $34.6 million during FY2023, and its lowest value of -$17.1 million during FY2021.
  • Over the past 3 years, Cartesian Therapeutics' median Cash from Investing Activities value was -$8.7 million (recorded in 2024), while the average stood at $3.6 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 2,213.09% in 2021, then soared by 330.70% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Cash from Investing Activities stood at -$741,000 in 2020, then crashed by 2,213.09% to -$17.1 million in 2021, then increased by 12.47% to -$15.0 million in 2022, then spiked by 330.70% to $34.6 million in 2023, then tumbled by 125.26% to -$8.7 million in 2024.